OUR APPROACH TO INNOVATION
We are reimagining what innovation looks like in the life sciences and are committed to providing the tools and expertise and that can inspire an infinite number of scientific solutions.

Innovation is at the core of the value that we deliver to our customers. Our business is research driven and innovation focused. In 2019, we invested 276 million Euro in R&D which supported our innovation in launching 18,500 products – products designed to meet our customers' most unmet needs – from antibodies to water purification systems.

This approach to innovation has led to the creation of three Promise Ventures, entrepreneurial businesses with start-up cultures that give us freedom in a framework to accelerate future growth.

Connected Labs create a digital ecosystem in the lab to solve the biggest pain points in data collection, documentation and inventory management.

With today’s labs of the future, laboratory informatics has leveraged technology and accelerated discovery by optimizing operations for our scientists and customers. Optimized workflows empowered by connectivity and efficiency are enhancing digital lab productivity. R&D expertise, combined with a comprehensive portfolio, allows us to deliver innovative technologies that make research and biotech production simpler, faster and safer.

From our BrightLab™ connected electronic lab notebook to our LANEXO™ lab management system to the unified and efficient access to lab data made possible by BSSN Software, which we acquired in 2019, we offer customers a variety of comprehensive, digital products and IoT solutions for safety, compliance, and inventory and instrument management.

Gene Editing and Novel Modalities develop offerings to support the rapidly emerging areas of gene editing and novel modalities and to become the recognized thought leader in the area.

Since the human genome was fully decoded 16 years ago, gene editing and novel modalities have rapidly evolved. Cell and gene therapies provide life-saving treatments to many patients. Our biopharmaceutical and biomanufacturing services address all phases of such therapeutic developments, which in turn help to deliver leading-edge, regenerative medicines to our customers.

We continue to invest in viral and gene therapies from clinical to commercial scale, which have transitioned from a niche industry to the cornerstone of the future of biopharmaceuticals. With CRISPR technology, the DNA of an organism can be edited; furthermore, its gene sequences within a cell can be separated or even replaced. These possibilities are coupled with enormous responsibility; we support research with genome editing in compliance with statutory regulations and careful consideration of ethical standards, and with a clearly defined bioethics policy.

BioReliance® End-to-End Solutions serve as the one-stop shop to fast-growing biotechs to manufacture biologic drugs across development phases.

Factors such as an aging global population and an increase in chronic diseases are catalysts for a new era of advanced discovery in drug manufacturing. Developments in biologics and therapies have great potential in treating illnesses where few or no other options are available. Despite this promising potential, the clinical development journey of a new biologic is a long and challenging process that we are working to strengthen and evolve.

To support development, our BioContinuum™ Platform is ushering in the next generation of bioprocessing that is connected and fully continuous. As a result, our strategic building blocks, which include our BioContinuum™ Platform, have the potential to accelerate access to recently developed, life-saving therapies that address the healthcare needs of underserved populations.

COLLABORATION DRIVES INNOVATION
Our M Lab™ Collaboration Centers offer vibrant collaboration spaces where our customers can explore ideas, learn innovative techniques, and work side by side with our scientists and engineers to solve critical process development challenges. This global network of non-GMP labs, designed specifically for customers, offer the flexibility to troubleshoot and test in our facility without impacting your production line. Located in key biopharma hubs around the world, our experts are ready to collaborate with your experts to solve your toughest problems – together.

Learn more about our M Lab™ Collaboration Centers.
 
M Lab™ Collaboration Centers
€276K invested in R&D
2,000 R&D employees
18,500 new products
10 M Lab™ Collaboration Centers Latest Stories